RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/28634224http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/28634224http://www.w3.org/2000/01/rdf-schema#comment"Burkitt lymphoma/leukemia cells carry t(8;14)(q24;q32) chromosomal translocation encoding IGH/MYC, which results in the constitutive expression of the MYC oncogene. Here, it is demonstrated that untreated and cytarabine (AraC)-treated IGH/MYC-positive Burkitt lymphoma cells accumulate a high number of potentially lethal DNA double-strand breaks (DSB) and display low levels of the BRCA2 tumor suppressor protein, which is a key element of homologous recombination (HR)-mediated DSB repair. BRCA2 deficiency in IGH/MYC-positive cells was associated with diminished HR activity and hypersensitivity to PARP1 inhibitors (olaparib, talazoparib) used alone or in combination with cytarabine in vitro Moreover, talazoparib exerted a therapeutic effect in NGS mice bearing primary Burkitt lymphoma xenografts. In conclusion, IGH/MYC-positive Burkitt lymphoma/leukemia cells have decreased BRCA2 and are sensitive to PARP1 inhibition alone or in combination with other chemotherapies.Implications: This study postulates that IGH/MYC-induced BRCA2 deficiency may predispose Burkitt lymphoma cells to synthetic lethality triggered by PARP1 inhibitors.Visual Overview: http://mcr.aacrjournals.org/content/molcanres/15/8/967/F1.large.jpgMol Cancer Res; 15(8); 967-72. ©2017 AACR."xsd:string
http://purl.uniprot.org/citations/28634224http://purl.org/dc/terms/identifier"doi:10.1158/1541-7786.mcr-16-0468"xsd:string
http://purl.uniprot.org/citations/28634224http://purl.uniprot.org/core/author"Martin K."xsd:string
http://purl.uniprot.org/citations/28634224http://purl.uniprot.org/core/author"Zhao H."xsd:string
http://purl.uniprot.org/citations/28634224http://purl.uniprot.org/core/author"Skorski T."xsd:string
http://purl.uniprot.org/citations/28634224http://purl.uniprot.org/core/author"Sullivan-Reed K."xsd:string
http://purl.uniprot.org/citations/28634224http://purl.uniprot.org/core/author"Nieborowska-Skorska M."xsd:string
http://purl.uniprot.org/citations/28634224http://purl.uniprot.org/core/author"Wasik M.A."xsd:string
http://purl.uniprot.org/citations/28634224http://purl.uniprot.org/core/author"Piwocka K."xsd:string
http://purl.uniprot.org/citations/28634224http://purl.uniprot.org/core/author"Tempera I."xsd:string
http://purl.uniprot.org/citations/28634224http://purl.uniprot.org/core/author"Podszywalow-Bartnicka P."xsd:string
http://purl.uniprot.org/citations/28634224http://purl.uniprot.org/core/author"Dasgupta Y."xsd:string
http://purl.uniprot.org/citations/28634224http://purl.uniprot.org/core/author"Hulse M."xsd:string
http://purl.uniprot.org/citations/28634224http://purl.uniprot.org/core/author"Maifrede S."xsd:string
http://purl.uniprot.org/citations/28634224http://purl.uniprot.org/core/author"Gritsyuk D."xsd:string
http://purl.uniprot.org/citations/28634224http://purl.uniprot.org/core/author"Lupey-Green L.N."xsd:string
http://purl.uniprot.org/citations/28634224http://purl.uniprot.org/core/author"Langer S.K."xsd:string
http://purl.uniprot.org/citations/28634224http://purl.uniprot.org/core/author"Nejati R."xsd:string
http://purl.uniprot.org/citations/28634224http://purl.uniprot.org/core/date"2017"xsd:gYear
http://purl.uniprot.org/citations/28634224http://purl.uniprot.org/core/name"Mol Cancer Res"xsd:string
http://purl.uniprot.org/citations/28634224http://purl.uniprot.org/core/pages"967-972"xsd:string
http://purl.uniprot.org/citations/28634224http://purl.uniprot.org/core/title"IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors."xsd:string
http://purl.uniprot.org/citations/28634224http://purl.uniprot.org/core/volume"15"xsd:string
http://purl.uniprot.org/citations/28634224http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/28634224